About OncoImmunity
OncoImmunity is a Healthcare company based in Oslo (Norway) founded in 2014, and was acquired by NEC in July 2019. Machine-learning software for personalized cancer immunotherapy is developed. OncoImmunity has raised $7.37 million across 6 funding rounds from investors including NEC, European Union and EIC Fund. The company has 16 employees. OncoImmunity offers products and services including NEC Immune Profiler, NEC B-cell Epitope Predictor, and Digital Twin Simulations. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery. Its legal entity is NEC ONCOIMMUNITY AS.
Company details
OncoImmunity was established in 2014 in Oslo, Norway, as a bioinformatics firm. Machine-learning tools are utilized to predict immunogenic neoantigens, addressing gaps in personalized cancer immunotherapy. Patient selection for treatments is facilitated, and targets for vaccines and cell therapies are identified within actionable timelines. Operations focus on clinical applications in oncology, with incubation support from the Oslo Cancer Cluster.
- Headquarters Oslo, Norway
- Employees 16
- Stage Acquired
- SectorsHealthcare
- Website oncoimmunity.com
- Social LinkedIn X Facebook
- Acquired by NEC (Jul 2019)
- Legal Name Nec Oncoimmunity As
Products & Services of OncoImmunity
OncoImmunity offers a comprehensive portfolio of products and services, including NEC Immune Profiler, NEC B-cell Epitope Predictor, and Digital Twin Simulations.
AI tool for immune profiling in cancer vaccine research
Predicts epitopes for infectious disease vaccines
Simulates biological processes for therapy development
Funding Insights of OncoImmunity
OncoImmunity has successfully raised a total of $7.37M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $57.8 thousand completed in October 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $7.37M
- Total Rounds 6
- Last Round Grant — $57,804
- First Round $56,067
(Jun 2017)
- Investors Count 2
All 6 funding rounds of OncoImmunity with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2021 | $57,804 | Grant | – | – | |
| May 2019 | $2.46M | Grant | – | – | |
| Dec 2018 | $2.49M | Grant | – | – | – |
| Jul 2018 | $7.37M | Seed | – | – | – |
| Oct 2017 | $58,130 | Grant | – | – | |
| Jun 2017 | $56,067 | Grant | – | – |
3 investors in total: 3 institutional.
Investors in OncoImmunity
OncoImmunity has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include NEC, European Union and EIC Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government agency and accelerator focusing on innovative startups and SMEs | eicfund.eu | Brussels, Belgium | ||
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Cloud-based IT and networking solutions are provided globally. | 1899 | nec.com | Minato City, Japan |
Investor details for OncoImmunity
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of OncoImmunity
2 people are tracked at OncoImmunity (2 in leadership); the tracked headcount is 16.
| Name | Role | Group |
|---|---|---|
Heinz Lubenau | Chief Drug Development Officer | Leadership |
Richard Stratford | CEO & Co-Founder | Leadership |
Complete people profiles for OncoImmunity
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of OncoImmunity
4 dated milestones of OncoImmunity across 7 years, from founding to its latest funding, stage changes and deals.
- Founded OncoImmunity is founded.
- Funding First funding round of $56K.
- Exit Acquired by NEC.
- Funding Latest funding round, Grant, of $58K.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Oncoimmunity
Complete news archive for OncoImmunity
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OncoImmunity
OncoImmunity was founded in 2014 and raised its 1st funding round 3 years after it was founded.
OncoImmunity is headquartered in Oslo, Norway. It is registered at Oslo, Oslo, Norway.
OncoImmunity is a funded company, having raised a total of $7.37M across 6 funding rounds to date. The company's 1st funding round was a Grant of $56.07K, raised on Jun 2017.
OncoImmunity has 16 employees.
Annual revenue of OncoImmunity is $1.34M as on Mar 31, 2022.
OncoImmunity was established in 2014 in Oslo, Norway, as a bioinformatics firm. Machine-learning tools are utilized to predict immunogenic neoantigens, addressing gaps in personalized cancer immunotherapy. Patient selection for treatments is facilitated, and targets for vaccines and cell therapies are identified within actionable timelines. Operations focus on clinical applications in oncology, with incubation support from the Oslo Cancer Cluster.
OncoImmunity offers NEC Immune Profiler, NEC B-cell Epitope Predictor, and Digital Twin Simulations.
OncoImmunity has 3 investors. Key investors include NEC, European Union, and EIC Fund.
OncoImmunity operates through Nec Oncoimmunity As.
Yes. OncoImmunity was acquired by NEC in July 2019.